I work for “medium pharma”. We spend between 1 and 5 dollars per experiment (depending on the cell type). We run close to 2 MILLION experiments every week. We are still years away from any of those experiments yielding a safe compound that can move on to human trials, assuming we don’t run out of money first.
Targeting drugs for rare diseases won’t be profitable until we achieve proper high-throughput experimentation, analysis, and somehow streamline the FDA approval process. The government needs to fund academic research on these diseases, but no university lab can match the kind of experiment production that we’re already doing in industry.
Very few drugs are largely government funded. The government funds basic research, but it won’t fund clinical trials. Pharma companies are almost entirely responsible for clinical trials, and they are way, way more expensive than basic research.
Yup.
I work for “medium pharma”. We spend between 1 and 5 dollars per experiment (depending on the cell type). We run close to 2 MILLION experiments every week. We are still years away from any of those experiments yielding a safe compound that can move on to human trials, assuming we don’t run out of money first.
Targeting drugs for rare diseases won’t be profitable until we achieve proper high-throughput experimentation, analysis, and somehow streamline the FDA approval process. The government needs to fund academic research on these diseases, but no university lab can match the kind of experiment production that we’re already doing in industry.
What do you think of Medicare price negotiation efforts? Or efforts to make largely government funded drugs patent free?
Very few drugs are largely government funded. The government funds basic research, but it won’t fund clinical trials. Pharma companies are almost entirely responsible for clinical trials, and they are way, way more expensive than basic research.